Cargando…

Tocilizumab for severe COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Lipworth, Brian J, Chan, Rory, Kuo, Chris RuiWen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431124/ https://www.ncbi.nlm.nih.gov/pubmed/32838325 http://dx.doi.org/10.1016/S2665-9913(20)30283-6

Ejemplares similares

Inhaled Corticosteroids and COVID-19
por: Lipworth, Brian, et al.
Publicado: (2020)

COVID-19: Start with the nose
por: Lipworth, Brian, et al.
Publicado: (2020)

Sex Hormones and Asthma: Don’t Forget Progesterone
por: Lipworth, Brian, et al.
Publicado: (2020)

Don’t Forget about Facilitatory Effects of Corticosteroids on β(2)-Adrenoceptors in Acute Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

Resistance Heterogeneity and Small Airway Asthma Phenotype
por: Lipworth, Brian, et al.
Publicado: (2019)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Systemic IL-6 and Severe Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

Type 2 Asthma Inflammation and COVID-19: A Double Edged Sword
por: Lipworth, Brian, et al.
Publicado: (2021)

Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection
por: Lipworth, Brian, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on
por: Lipworth, Brian, et al.
Publicado: (2020)

Does unified allergic airway disease impact on lung function and type 2 biomarkers?
por: Kuo, Chris RuiWen, et al.
Publicado: (2019)

High-dose budesonide for early COVID-19
por: Lipworth, Brian, et al.
Publicado: (2021)

Predicting Severe Outcomes in COVID-19
por: Lipworth, Brian, et al.
Publicado: (2020)

Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma
por: Lipworth, Brian, et al.
Publicado: (2023)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy
por: Ammirati, Enrico, et al.
Publicado: (2020)

I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements
por: Kuo, Chris RuiWen, et al.
Publicado: (2019)

Current appraisal of single inhaler triple therapy in COPD
por: Lipworth, Brian, et al.
Publicado: (2018)

“Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case–control study from a tertiary care hospital”
por: Barthwal, M. S., et al.
Publicado: (2023)

Tocilizumab in COVID-19: finding the optimal route and dose
por: Jain, Siddharth, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
por: Mastroianni, Fiore
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Severe Hypoxemia in Early COVID-19 Pneumonia
por: Bhatia, Pradeep, et al.
Publicado: (2020)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

Provision of holistic care after severe COVID-19 pneumonia
por: McPeake, Joanne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g3q9r5869u0r0928h9ck9u0lrn